Detalles de la búsqueda
1.
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Proc Natl Acad Sci U S A
; 121(17): e2321898121, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38625939
2.
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol
; 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38493021
3.
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
Gynecol Oncol
; 187: 12-20, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703673
4.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol
; 168: 157-165, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36442427
5.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol
; 170: 38-45, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610380
6.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706643
7.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol
; 169: 98-105, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525930
8.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol
; 172: 65-71, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958197
9.
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Int J Mol Sci
; 24(10)2023 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37240216
10.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol
; 166(1): 117-125, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35599167
11.
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
Gynecol Oncol
; 170: 334, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906375
12.
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy.
Gynecol Oncol Rep
; 48: 101219, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37325293
13.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Mol Cancer Ther
; 22(12): 1404-1412, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676984
Resultados
1 -
13
de 13
1
Próxima >
>>